Every 10-Q that Tenon Medical, Inc. (TNON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TNON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNON filings page.
Tenon Medical, Inc. reported higher revenue but continuing losses for the quarter ended June 30, 2026. Quarterly revenue was $1.3 million, up from $0.6 million a year earlier, with gross margin improving to 64% from 43% as procedure volumes grew and the SImmetry+ system contributed.
The company still operates at a loss, with a net loss of $4.1 million for the quarter and $7.5 million for the first half of 2026. Cash and cash equivalents fell to $1.7 million, while total liabilities increased to $11.7 million, resulting in a stockholders’ deficit of $1.7 million. Management states there is substantial doubt about the ability to continue as a going concern, even after receiving $3.6 million of net proceeds from a July 2026 equity offering.
Tenon issued 20% original issue discount senior convertible promissory notes in March 2026, creating a $475 thousand derivative liability. The company also effected a 1-for-35 reverse stock split in August 2026 to address Nasdaq minimum bid-price requirements and previously regained compliance with Nasdaq’s stockholders’ equity rule following the July offering. Disclosure controls and procedures are deemed not effective due to a material weakness from limited segregation of duties.
Tenon Medical, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $1.38 million from $0.73 million, driven by more surgical procedures and added sales from the SImmetry+ SI Joint Fusion System. Gross margin improved to 69%, reflecting better overhead absorption.
The company still posted a net loss of $3.48 million and used $2.96 million of cash in operating activities. Cash and cash equivalents were $4.61 million. Management states there is substantial doubt about Tenon’s ability to continue as a going concern and discloses a Nasdaq notice for failing to maintain the $1.00 minimum bid price. During the quarter Tenon raised $4.3 million of gross proceeds from senior convertible promissory notes, adding a derivative liability, and later issued 276,228 shares for an acquisition milestone.
Tenon Medical (TNON) reported Q3 results and completed two asset acquisitions to expand its SI joint portfolio. Revenue was $1.173 million versus $0.887 million a year ago, with gross margin improving to 66% from 47% as higher volumes reduced fixed production costs per unit. Net loss was $3.339 million compared with $3.184 million.
Cash and cash equivalents were $3.442 million as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern for one year after issuance, and plans to seek additional financing.
In August, Tenon acquired substantially all assets of SiVantage and SIMPL (treated as a single business combination) for total consideration of $3.127 million, including $0.75 million in cash, 710,300 shares, and contingent consideration; goodwill recorded was $2.407 million. As a subsequent event, the company announced a $2.85 million PIPE financing, issuing 2,217,904 common shares and warrants to purchase 2,217,904 shares at a combined price of $1.285 per share-and-warrant, with warrants exercisable at $1.16.
Shares outstanding were 8,605,740 as of November 13, 2025.
Tenon Medical, Inc. reported quarterly revenue of $564,000 and six‑month revenue of $1.29 million, down from $901,000 and $1.62 million a year earlier, driven by fewer procedures using The Catamaran System. Gross profit fell and margins compressed, while the company recorded a net loss of $2.769 million for the quarter and $6.385 million for the six months, contributing to an accumulated deficit of $75.1 million. Cash and cash equivalents totaled $7.846 million at June 30, 2025, bolstered by $6.2 million of net financing in the first half of 2025.
Management discloses substantial doubt about the company’s ability to continue as a going concern for the next 12 months and plans to seek additional capital. Subsequent events include the acquisitions of SImmetry (closed Aug 1, 2025) and SIMPL (closed Aug 4, 2025), which transfer IP and product assets for cash, shares and royalty arrangements; the transactions also include executive hires with equity compensation. The company reported a material weakness in internal controls related to segregation of duties.